United Therapeutics Expands Immune Therapy Pipeline With Thymmune
United Therapeutics Corp. (NASDAQ: UTHR ) said Thursday it has acquired privately held Thymmune Therapeutics. Thymmune is a preclinical biotechnology company developing regenerative thymic cell therapies designed to restore immune function and improve transplant outcomes. Read Also: FDA Approval Positions United Therap